Deze IPO is nog niet vertaald in uw taal [en]
TenNor Therap-B logo

TenNor Therap-B

06872 · HKEX
Vermeld

Dano Pharmaceutical is a biotechnology company approaching the commercialization stage, focusing on the discovery, development and commercialization of differentiated innovative pharmaceutical product…

Vermeld

IPO-tijdlijn

  1. OpenenMay 14
  2. SluitenMay 19
  3. ToezeggingMay 21
  4. BetalingMay 22
  5. LijstMay 22

Kerngegevens

Uitgifteprijs

HKD 75.70

Min. inschrijfkosten

HKD 3,823.17

Uitgegeven aandelen

8.86M

Lotgrootte

50

Totale verhoging

HKD 670.4M

Geschatte marktplafond

HKD 3.92B

Overheidstoewijzing

10.0%

Internationale plaatsing

90.0%

Bedrijfsoverzicht

Dano Pharmaceutical is a biotechnology company approaching the commercialization stage, focusing on the discovery, development and commercialization of differentiated innovative pharmaceutical products to address unmet clinical needs in the fields of bacterial infections and bacterial metabolism‑related diseases.

Gebruik van opbrengsten

1、71.0% or approximately HK$395.7 million will be used for the research, development, registration filing and commercialisation of the Company’s core products;

2、7.0% or approximately HK$39.2 million will be used to fund the research and development of the oral formulation of TNP‑2092;

3、7.3% or approximately HK$40.9 million will be used for the research and development of other candidate products of the Company;

4、7.2% or approximately HK$40.2 million will be used for the construction of the Company’s own manufacturing plant;

5、7.5% or approximately HK$41.8 million will be used as working capital and for other general corporate purposes.

Sponsor Track record

Track-record gegevens worden vernieuwd.

Bemiddelaars en documenten

Sponsors

  • 中信證券(香港)有限公司
  • 農銀國際融資有限公司

Underwriters

  • 中信里昂證券有限公司
  • 農銀國際證券有限公司
  • 華興證券(香港)有限公司
  • 富途證券國際(香港)有限公司
  • 老虎證券(香港)環球有限公司

Prospectus PDF

Prospectus PDF →

Hoeksteenbeleggers

  • AMR Action Fund, L.P.
  • 华圆管理咨询(香港)有限公司
  • AMR Action Fund, SCSp
  • 东方资产管理(香港)有限公司
  • 骏升环球有限公司

Total

0

37.3% of placement

BBX neemt niet deel aan het toewijzingsproces voor een IPO die op deze pagina wordt vermeld. Deze pagina is uitsluitend ter informatie en is geen beleggingsadvies.